Verified Nov 2026
Other
·
Danbury, Connecticut
·
Since 1991
MannKind Corporation is a biopharmaceutical company headquartered in Danbury, Connecticut, founded in 1991 and publicly traded under the ticker MNKD. It employs between 500 and 1,000 people and focuses on pulmonary drug delivery for endocrine and orphan lung diseases. Its product portfolio includes Afrezza, an inhaled insulin, and V-Go, a wearable insulin delivery device. In August 2026, the Danbury-based company was reported to be expanding its workforce and manufacturing amid new product launches.
MannKind Corporation at a glance
Revenue
349.0M
Employees
500-1,000
Founded
1991
Headquarters
Danbury, Connecticut
Ownership
Publicly traded (NASDAQ: MNKD)
Industries
Automotive
Electric Vehicles
Medical
Industrial Equipment
Overview
MannKind Corporation is a biopharmaceutical company headquartered in Danbury, Connecticut, founded in 1991 and publicly traded under the ticker MNKD. It employs between 500 and 1,000 people and focuses on pulmonary drug delivery for endocrine and orphan lung diseases. Its product portfolio includes Afrezza, an inhaled insulin, and V-Go, a wearable insulin delivery device. In August 2026, the Danbury-based company was reported to be expanding its workforce and manufacturing amid new product launches.
At a glance
Attribute | Detail |
|---|---|
Founded | 1991 |
Headquarters | Danbury, Connecticut |
Employees | 500-1,000 |
Revenue | 349.0M |
Ownership | Publicly traded (NASDAQ: MNKD) |
What MannKind Corporation makes
The company develops inhalation drug delivery systems built on its proprietary Technosphere formulation platform and its Dreamboat inhalation device technology.
Products and capabilities described on the company's own site include Mold (source: mannkindcorp.com).
Latest developments
2026-11-05 — MannKind Reports Third Quarter 2026 Financial Results and Provides Business Update | MannKind Corporation (mannkindcorp.com)
2026-09-09 — MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management | MannKind Corporation (mannkindcorp.com)
2026-08-07 — Danbury biopharma company expands workforce, manufacturing amid new product launches (hartfordbusiness.com)
2026-05-06 — MannKind Announces Ralinepag Dry Powder Inhalation (DPI) (globenewswire.com)
2026-05-06 — MannKind Reports First Quarter 2026 Financial Results and (globenewswire.com)
2025-10-07 — MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care | MannKind Corporation (mannkindcorp.com)
Company details
MannKind is publicly listed under the ticker MNKD and licensed its Tyvaso DPI treatment for pulmonary arterial hypertension to United Therapeutics. MannKind Corporation was founded in 1991, has an estimated 500-1,000 employees, and is headquartered in Danbury, Connecticut.
Frequently asked questions
What does MannKind Corporation do?
MannKind Corporation is a biopharmaceutical company headquartered in Danbury, Connecticut, founded in 1991 and publicly traded under the ticker MNKD. It employs between 500 and 1,000 people and focuses on pulmonary drug delivery for endocrine and orphan lung diseases. Its product portfolio includes Afrezza, an inhaled insulin, and V-Go, a wearable insulin delivery device. In August 2026, the Danbury-based company was reported to be expanding its workforce and manufacturing amid new product launches.
Where is MannKind Corporation headquartered?
MannKind Corporation is headquartered in Danbury, Connecticut (1 Casper St, Danbury, Connecticut, 06810-6903).
When was MannKind Corporation founded?
MannKind Corporation was founded in 1991.
How big is MannKind Corporation?
MannKind Corporation has an estimated 500-1,000 employees, with revenue in the 349.0M range.
Is MannKind Corporation publicly traded?
Publicly traded (NASDAQ: MNKD). Public financial figures are drawn from its filings.
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile comes from a public-data sample of around 1,000 companies. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.